Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access through a Named Patient Program. A multicentric observational retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Argnani, Lisa, Broccoli, Alessandro, Pellegrini, Cinzia, Fabbri, Alberto, Puccini, Benedetta, Bruna, Riccardo, Tisi, Maria Chiara, Masia, Francesco, Flenghi, Leonardo, Nizzoli, Maria Elena, Musso, Maurizio, Salerno, Marilena, Scalzulli, Potito Rosario, Dessi’, Daniela, Ferrarini, Isacco, Pennese, Elsa, Lucchini, Elisa, Rossi, Francesca Gaia, Minoia, Carla, Gherlinzoni, Filippo, Musto, Pellegrino, Patti, Caterina, Stefoni, Vittorio, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663137/
https://www.ncbi.nlm.nih.gov/pubmed/36398133
http://dx.doi.org/10.1097/HS9.0000000000000798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663137/
https://www.ncbi.nlm.nih.gov/pubmed/36398133
http://dx.doi.org/10.1097/HS9.0000000000000798

Ejemplares similares